Bayesian analysis of longitudinal studies with treatment by indication

TL;DR

This paper introduces a Bayesian framework to infer causal effects in longitudinal observational studies with treatment by indication, addressing missing treatment initiation times and incorporating uncertainty in the analysis.

Contribution

It proposes a novel Bayesian method to estimate causal effects when treatment initiation times are only observed for treated units, separating the assignment process from the outcome mechanism.

Findings

Applied to VA data, estimated mortality effects of PDE5I prescriptions.

Demonstrated the method's ability to handle missing treatment times and uncertainty.

Provided insights into inappropriate medication use in pulmonary hypertension patients.

Abstract

It is often of interest in observational studies to measure the causal effect of a treatment on time-to-event outcomes. In a medical setting, observational studies commonly involve patients who initiate medication therapy and others who do not, and the goal is to infer the effect of medication therapy on time until recovery, a pre-defined level of improvement, or some other time-to-event outcome. A difficulty with such studies is that the notion of a medication initiation time does not exist in the control group. We propose an approach to infer causal effects of an intervention in longitudinal observational studies when the time of treatment assignment is only observed for treated units and where treatment is given by indication. We present a framework for conceptualizing an underlying randomized experiment in this setting based on separating the process that governs the time of study arm assignment from the mechanism that determines the assignment. Our approach involves inferring the missing times of assignment followed by estimating treatment effects. This approach allows us to incorporate uncertainty about the missing times of study arm assignment, which induces uncertainty in both the selection of the control group and the measurement of time-to-event outcomes for these controls. We demonstrate our approach to study the effects on mortality of inappropriately prescribing phosphodiesterase type 5 inhibitors (PDE5Is), a medication contraindicated for groups 2 and 3 pulmonary hypertension, using administrative data from the Veterans Affairs (VA) health care system.